Abstract
Chronic inflammatory demyelinating polyneuropathy (CIDP) is an acquired neurological disorder characterized clinically by weakness and impaired sensory function evolving over 2 months or more, loss or significant decrease in deep tendon reflexes, and by electrophysiological evidence of peripheral nerve demyelination. Expeditious diagnosis and treatment of CIDP early in the disease course is critical such that irreversible disability can be avoided. Intravenous immunoglobulin (IVIG) is one first-line and maintenance therapy option for CIDP. The US Food & Drug Administration's (FDA's) approval of subcutaneous immunoglobulin (SCIG) in 2018 provides patients with CIDP more treatment options for maintenance therapy. The different options for administration of IG treatment create the need for information to assist clinicians and patients in choosing the optimal therapeutic approach. Considerations for pharmacokinetics, administration procedures, adverse events, patient variables, and cost will all be discussed in this article.
Original language | English (US) |
---|---|
Article number | 116497 |
Journal | Journal of the Neurological Sciences |
Volume | 408 |
DOIs | |
State | Published - Jan 15 2020 |
Bibliographical note
Funding Information:Dr. Wolfe is a consultant for Grifols, Takeda. Research support from CSL Behring.
Funding Information:
Dr. Allen is a consultant for Argenyx, CSL Behring, Biotest, Akcea. Dr. Freimer is on advisory boards for ARGENX, Alexion, CSL Behring; research Funding: Argenx, UCB, Ra, Alexion, Catalyst,Grifols, Acceleron,Momenta, Octapharma, Orphazyme, Alnylum, Amicus. Dr. Wolfe is a consultant for Grifols, Takeda. Research support from CSL Behring . Drs. Gelinas and Runken are employees of Grifols SSNA. Preparation of this manuscript was funded by Grifols (Research Triangle Park, NC), a manufacturer of SCIG and IVIG.
Publisher Copyright:
© 2019 The Authors
Keywords
- Chronic inflammatory demyelinating polyneuropathy
- Intravenous immunoglobulin
- Maintenance therapy
- Route of administration comparison
- Subcutaneous immunoglobulin
PubMed: MeSH publication types
- Journal Article
- Review